Conduct↦Management↦Amendment↦Patient Information
What is it? Why is it important?
Based on a protocol amendment the Participant Information Sheet (PIS) and the Informed Consent Form (ICF) might become incomplete, lacking amended information relevant to participants. As consequence these document must be adapted accordingly.
In order to protect the rights and safety (e.g. risk-benefit ratio) of study participants, the SP-INV or Site-INV is responsible to inform participants of any protocol changes, that could potentially affect them including their willingness to participate in the study.
Amended PIS/ICF documents require that participants re-consent to changes by dating and signing the amended ICF. If applicable, a participant’s legal representative should also be informed in a timely manner, regarding any changes affecting the study participant.
What do I need to do?
As a SP-INV during study conduct:
- Ensure PIS/ICF or any other written information provided to participants is revised whenever new and important information becomes available
- If required, make applicable changes to the PIS/ICF documents or any other relevant written material handed out to participants (e.g. information leaflets)
- In order to track your documents during study conduct ensure documents are identified as amended version(s) (e.g. document identification)
- Submit amended documents in track-change to the Ethics Committee (EC) for approval
As a Site-INV responsible for a particular study site ensure:
- Study site only has access to the amended and EC approved documents (e.g. document management)
- Archived and outdated documents are clearly identifiable from current or active ones (e.g. document management
- Study staff is trained on the amended documents (i.e. document training in a training-log)
- Changes (safety amendments excluded) are only implemented after the Site-INV and the participant have dated and signed the revised ICF
More
Example
During study conduct, the SP-INV would like to make a change to the study protocol. For the ongoing study, the SP-INV would like to collect an additional blood sample (5 ml whole blood). This change will affect study participants as they will be asked to donate additional blood. Thus, an adaptation to PIS/ICF becomes necessary. Participants must be informed and consent to this change before additional blood samples can be collected. The participant retains the right to abstain from giving consent (e.g. safety amendments excluded).
The following procedures are set in motion:
- PIS and ICF are adapted accordingly and submitted to EC for approval
- Upon EC approval participants are informed about the aim of an additional blood sample including applicable safety concerns
- Participants are asked to give consent to an additional blood sample
- Participants are given time to decide whether to agree or not
- Blood is only be collected form participants who agreed and signed the revised ICF
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- 2.8.2. Revision of informed consent
- 3.8.2. EC change approval
ISO 14155:2020 Medical devices (access liable to cost) - see in particular sections
- 5.8.6 New information
- 10.5 Informed consent procedure